Inactivating mutations in GATOR1 components DEPDC5 and NPRL2 have also been identified in glioblastomas and ovarian cancers [68], and reduced expression of NPRL2 has been detected in a number of other cancers [105–110]. Here, DEPDC5 is linked to ovarian carcinoma.